K-Ras(G12C) inhibitor 12|CAS 1469337-95-8
K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).
Product name: K-Ras(G12C) inhibitor 12|Purity>98%| CAS: 1469337-95-8|Molecule Formular: C15H17ClIN3O3|MW: 449.67|Other Namess:
For research only, not for human use.
2016年7月14日星期四
CP21 (CP21R7)|CAS 125314-13-8 | inhibitor
CP21 (CP21R7)|CAS 125314-13-8 | inhibitor
Product name: CP21 (CP21R7)|Purity>98%| CAS: 125314-13-8|Molecule Formular: C19H15N3O2|MW: 317.34|Other Namess:
For research only, not for human use.
Product name: CP21 (CP21R7)|Purity>98%| CAS: 125314-13-8|Molecule Formular: C19H15N3O2|MW: 317.34|Other Namess:
For research only, not for human use.
Cl-amidine|PAD Inhibitor
Cl-amidine|PAD Inhibitor
Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays.
Product name: Cl-amidine|Purity>98%| CAS: 1043444-18-3|Molecule Formular: C16H20ClF3N4O4|MW: 424.8|Other Namess:
Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays. It preferentially inactivates the calcium bound form of PAD4 in an irreversible manner, and is shown to complete with BAEE for the active site residue of this enzyme. A small but significant reduction in the efficiency of p300GDB-GRIP1 interaction is observed in transiently transfected CV-1 cells treated with Cl-amidine at concentrations between 25 µM and 200 µM, in vivo . Furthermore, this compound (200 µM) together with HDAC inhibitor SAHA (0.4 µM) has shown additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner in U2OS cells.
For research only, not for human use.
Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays.
Product name: Cl-amidine|Purity>98%| CAS: 1043444-18-3|Molecule Formular: C16H20ClF3N4O4|MW: 424.8|Other Namess:
Cl-amidine is a cell-permeable compound that acts as a pan PAD inhibitor (IC50 = 0.8 µM, 6.2 µM and 5.9 µM for PAD1, PAD3, and PAD4, respectively) in enzymatic assays. It preferentially inactivates the calcium bound form of PAD4 in an irreversible manner, and is shown to complete with BAEE for the active site residue of this enzyme. A small but significant reduction in the efficiency of p300GDB-GRIP1 interaction is observed in transiently transfected CV-1 cells treated with Cl-amidine at concentrations between 25 µM and 200 µM, in vivo . Furthermore, this compound (200 µM) together with HDAC inhibitor SAHA (0.4 µM) has shown additive effects in inducing p21, GADD45, and PUMA expression and inhibiting cancer cell growth in a p53-dependent manner in U2OS cells.
For research only, not for human use.
BI-7273|BI7273|BRD9 BD Inhibitor
BI-7273|BI7273|BRD9 BD Inhibitor
BI-7273 is a potent, selective, and cell-permeable BRD9 BD Inhibitor.
Product name: BI-7273|Purity>98%| CAS: 1883429-21-9|Molecule Formular: C20H23N3O3 |MW: 353.41|Other Namess: BI 7273,BI7273
BI-7273 is a potent, selective, and cell-permeable BRD9 BD Inhibitor with Kd (BRD9, ITC) = 15 nM and Kd (BRD9, DiscoveRx) = 0.75 nM. IC50 (BRD9 alpha assay ) = 19nm. BI-7273 proves to be invaluable as tools to further explore BRD9 biology. Components of the chromatin remodelling SWI/SNF complex are recurrently mutated in tumours, suggesting that altering the activity of the complex plays a role in oncogenesis. BRD9, a SWI/SNF subunit, play an important role in leukemia growth. The BRD9 bromodomain (BD) was shown to be required for the proliferation of acute myeloid leukemia (AML) cells.
For research only, not for human use.
BI-7273 is a potent, selective, and cell-permeable BRD9 BD Inhibitor.
Product name: BI-7273|Purity>98%| CAS: 1883429-21-9|Molecule Formular: C20H23N3O3 |MW: 353.41|Other Namess: BI 7273,BI7273
BI-7273 is a potent, selective, and cell-permeable BRD9 BD Inhibitor with Kd (BRD9, ITC) = 15 nM and Kd (BRD9, DiscoveRx) = 0.75 nM. IC50 (BRD9 alpha assay ) = 19nm. BI-7273 proves to be invaluable as tools to further explore BRD9 biology. Components of the chromatin remodelling SWI/SNF complex are recurrently mutated in tumours, suggesting that altering the activity of the complex plays a role in oncogenesis. BRD9, a SWI/SNF subunit, play an important role in leukemia growth. The BRD9 bromodomain (BD) was shown to be required for the proliferation of acute myeloid leukemia (AML) cells.
For research only, not for human use.
PBTZ169|PBTZ-169|DprE1 inhibitor
SKF96365|SKF-96365|cas 130495-35-1
GSK2983559|GSK-2983559
GSK2983559|GSK-2983559
Product name: GSK2983559|Purity>98%| CAS: N/A|Molecule Formular: C21H22N4O4S2|MW: 458.55|Other Namess: GSK-2983559,GSK 2983559
For research only, not for human use.
Product name: GSK2983559|Purity>98%| CAS: N/A|Molecule Formular: C21H22N4O4S2|MW: 458.55|Other Namess: GSK-2983559,GSK 2983559
For research only, not for human use.
GSK3175047|GSK-3175047
GSK3175047|GSK-3175047
Product name: GSK3175047|Purity>98%| CAS: N/A|Molecule Formular: C25H35N3O6S|MW: 505.63|Other Namess: GSK 3175047,GSK-3175047
For research only, not for human use.
Product name: GSK3175047|Purity>98%| CAS: N/A|Molecule Formular: C25H35N3O6S|MW: 505.63|Other Namess: GSK 3175047,GSK-3175047
For research only, not for human use.
GSK2814338|GSK-2814338
GSK2814338|GSK-2814338
Product name: GSK2814338|Purity>98%| CAS: N/A|Molecule Formular: C21H17F5N4O3|MW: 468.38|Other Namess: GSK2814338,GSK 2814338,GSK-2814338
For research only, not for human use.
Product name: GSK2814338|Purity>98%| CAS: N/A|Molecule Formular: C21H17F5N4O3|MW: 468.38|Other Namess: GSK2814338,GSK 2814338,GSK-2814338
For research only, not for human use.
BEBT-908（CUDC-908）|PI3K/HDAC inhibitor
BEBT-908（CUDC-908）|PI3K/HDAC inhibitor
BEBT-908（CUDC-908）is a novel PI3K/HDAC inhibitor.
Product name: BEBT-908（CUDC-908）|Purity>98%| CAS: 1235449-52-1|Molecule Formular: C23H25N9O3S|MW: 507.57|Other Namess: BEBT908,CUDC908,BEBT 908,CUDC 908
For research only, not for human use.
BEBT-908（CUDC-908）is a novel PI3K/HDAC inhibitor.
Product name: BEBT-908（CUDC-908）|Purity>98%| CAS: 1235449-52-1|Molecule Formular: C23H25N9O3S|MW: 507.57|Other Namess: BEBT908,CUDC908,BEBT 908,CUDC 908
For research only, not for human use.
GSK-3039294|Serum amyloid P component inhibitor
GSK-3039294|Serum amyloid P component inhibitor
GSK3039294 is a Serum amyloid P component inhibitor.
Product name: GSK3039294|Purity>98%| CAS: N/A|Molecule Formular: C30H44N2O14|MW: 656.68|Other Namess: GSK 3039294,GSK-3039294
For research only, not for human use.
GSK3039294 is a Serum amyloid P component inhibitor.
Product name: GSK3039294|Purity>98%| CAS: N/A|Molecule Formular: C30H44N2O14|MW: 656.68|Other Namess: GSK 3039294,GSK-3039294
For research only, not for human use.
GSK2110183|GSK-2110183|pan AKT inhibitor
GSK2110183|GSK-2110183|pan AKT inhibitor
GSK2110183 is an orally bioavailable, selective, ATP-competitive and potent pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.
Product name: GSK2110183|Purity>98%| CAS: 1047634-63-8|Molecule Formular: C18H16Cl2F2N4OS|MW: 445.31|Other Namess: GSK-2110183,GSK 2110183
GSK2110183 showed concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in BT474 (breast; ERBB2+, PIK3CA K111N) and LNCaP (prostate; PTEN null). Mice bearing BT474 breast tumor xenografts were dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which resulted in 8, 37 and 61% TGI, respectively. Similarly, mice treated with GSK2110183 at 10, 30 and 100 mg/kg resulted in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
For research only, not for human use.
GSK2110183 is an orally bioavailable, selective, ATP-competitive and potent pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.
Product name: GSK2110183|Purity>98%| CAS: 1047634-63-8|Molecule Formular: C18H16Cl2F2N4OS|MW: 445.31|Other Namess: GSK-2110183,GSK 2110183
GSK2110183 showed concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in BT474 (breast; ERBB2+, PIK3CA K111N) and LNCaP (prostate; PTEN null). Mice bearing BT474 breast tumor xenografts were dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which resulted in 8, 37 and 61% TGI, respectively. Similarly, mice treated with GSK2110183 at 10, 30 and 100 mg/kg resulted in 23, 37 and 97% TGI, respectively, of SKOV3 xenografts.
For research only, not for human use.
GSK3117391|GSK-3117391|HDAC inhibitor
GSK3117391|GSK-3117391|HDAC inhibitor
GSK3117391 is a HDAC inhibitor.
Product name: GSK3117391|Purity>98%| CAS: 1018673-42-1|Molecule Formular: C22H33N3O4|MW: 403.52|Other Namess: GSK 3117391,GSK-3117391
For research only, not for human use.
GSK3117391 is a HDAC inhibitor.
Product name: GSK3117391|Purity>98%| CAS: 1018673-42-1|Molecule Formular: C22H33N3O4|MW: 403.52|Other Namess: GSK 3117391,GSK-3117391
For research only, not for human use.
GSK1940029|stearoyl CoA desaturase 1 inhibitor
GSK1940029|stearoyl CoA desaturase 1 inhibitor
GSK1940029 is a stearoyl CoA desaturase 1 inhibitor.
Product name: GSK1940029|Purity>98%| CAS: N/A|Molecule Formular: C18H16Cl2N4O2|MW: 391.25|Other Namess: GSK-1940029,GSK 1940029
For research only, not for human use.
GSK1940029 is a stearoyl CoA desaturase 1 inhibitor.
Product name: GSK1940029|Purity>98%| CAS: N/A|Molecule Formular: C18H16Cl2N4O2|MW: 391.25|Other Namess: GSK-1940029,GSK 1940029
For research only, not for human use.
GSK2981278|GSK-2981278|ROR gamma inhibitor
GSK2981278|GSK-2981278|ROR gamma inhibitor
GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).
Product name: GSK2981278|Purity>98%| CAS: 1474110-21-8|Molecule Formular: C25H35NO5S|MW: 461.61|Other Namess: GSK-2981278,GSK 2981278
For research only, not for human use.
GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).
Product name: GSK2981278|Purity>98%| CAS: 1474110-21-8|Molecule Formular: C25H35NO5S|MW: 461.61|Other Namess: GSK-2981278,GSK 2981278
For research only, not for human use.
GSK2330672|GSK 2330672|ASBT inhibitor
GSK2330672|GSK 2330672|ASBT inhibitor
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) .
Product name: GSK2330672|Purity>98%| CAS: 1345982-69-5|Molecule Formular: C28H38N2O7S|MW: 546.68|Other Namess: GSK 2330672,GSK-2330672
GSK2330672 is a highly potent, nonabsorbable ASBT inhibitor with excellent aqueous solubility, selectivity, and developability properties for evaluation in safety studies and ultimately humans. GSK2330672 will be a valuable clinical tool for exploring the therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
in vivo: GSK2330672 results in potent inhibition of ASBT and very low oral absorption in the rat. GSK2330672 shows potent mouse and rat ASBT activity and was stable in GI stability assays. GSK2330672 is stable in the rodent GI tract and potently induced fecal bile acid excretion in mice, leading us to select these three compounds for mechanistic and efficacy studies in vivo in lean rats and Zucker Diabetic Fatty (ZDF) rats, respectively.
For research only, not for human use.
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) .
Product name: GSK2330672|Purity>98%| CAS: 1345982-69-5|Molecule Formular: C28H38N2O7S|MW: 546.68|Other Namess: GSK 2330672,GSK-2330672
GSK2330672 is a highly potent, nonabsorbable ASBT inhibitor with excellent aqueous solubility, selectivity, and developability properties for evaluation in safety studies and ultimately humans. GSK2330672 will be a valuable clinical tool for exploring the therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of patients with type 2 diabetes.
in vivo: GSK2330672 results in potent inhibition of ASBT and very low oral absorption in the rat. GSK2330672 shows potent mouse and rat ASBT activity and was stable in GI stability assays. GSK2330672 is stable in the rodent GI tract and potently induced fecal bile acid excretion in mice, leading us to select these three compounds for mechanistic and efficacy studies in vivo in lean rats and Zucker Diabetic Fatty (ZDF) rats, respectively.
For research only, not for human use.
GSK3008348|Alpha V beta 6 integrin inhibitor
GSK3008348|Alpha V beta 6 integrin inhibitor
GSK3008348 is an Integrin alphaV inhibitor.
Product name: GSK3008348|Purity>98%| CAS: 1629249-33-7|Molecule Formular: C29H38ClN5O2|MW: 524.1|Other Namess: GSK 3008348,GSK-3008348
For research only, not for human use.
GSK3008348 is an Integrin alphaV inhibitor.
Product name: GSK3008348|Purity>98%| CAS: 1629249-33-7|Molecule Formular: C29H38ClN5O2|MW: 524.1|Other Namess: GSK 3008348,GSK-3008348
For research only, not for human use.
SRT3025|SRT-3025|sirt1 activator
BDA-366|BDA366|Bcl2-BH4 Antagonist
BDA-366|BDA366|Bcl2-BH4 Antagonist
BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Product name: BDA-366|Purity>98%| CAS: 1821496-27-8|Molecule Formular: C24H29N3O4|MW: 423.5|Other Namess: BDA-366,BDA 366,BDA366
BDA-366 is a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo.
For research only, not for human use.
BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Product name: BDA-366|Purity>98%| CAS: 1821496-27-8|Molecule Formular: C24H29N3O4|MW: 423.5|Other Namess: BDA-366,BDA 366,BDA366
BDA-366 is a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo.
For research only, not for human use.
GDC-0084（RG7666）|5-HT1A/B/D receptor antagonist
GDC-0084（RG7666）|5-HT1A/B/D receptor antagonist
GDC-0084 （RG7666）, is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
Product name: GDC-0084（RG7666）|Purity>98%| CAS: 1382979-44-3 |Molecule Formular: C18H22N8O2 |MW: 382.43|Other Namess: RG7666; RG-7666; RG 7666; GDC-0084; GDC0084; GDC 0084
GDC-0084, also known as RG7666, is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis.
For research only, not for human use.
GDC-0084 （RG7666）, is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
Product name: GDC-0084（RG7666）|Purity>98%| CAS: 1382979-44-3 |Molecule Formular: C18H22N8O2 |MW: 382.43|Other Namess: RG7666; RG-7666; RG 7666; GDC-0084; GDC0084; GDC 0084
GDC-0084, also known as RG7666, is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis.
For research only, not for human use.
MK-4101|MK4101|SMO inhibitor
MK-4101|MK4101|SMO inhibitor
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.
Product name: MK-4101|Purity>98%| CAS: 935273-79-3|Molecule Formular: C24H24F5N5O|MW: 493.47|Other Namess: MK4101,MK 4101,MK-4101
For research only, not for human use.
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.
Product name: MK-4101|Purity>98%| CAS: 935273-79-3|Molecule Formular: C24H24F5N5O|MW: 493.47|Other Namess: MK4101,MK 4101,MK-4101
For research only, not for human use.
ABT-639|ABT639|T-type Ca2+ channel blocker
ABT-639|ABT639|T-type Ca2+ channel blocker
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).
Product name: ABT-639|Purity>98%| CAS: 1235560-28-7|Molecule Formular: C20H20ClF2N3O3S|MW: 455.91|Other Namess: ABT639,ABT 639
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).
in vitro: ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50 > 30 μM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents.
in vivo: Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED50 = 2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain. The antinociceptive profile of ABT-639 provides novel insights into the role of peripheral T-type (Cav3.2) channels in chronic pain states.
For research only, not for human use.
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).
Product name: ABT-639|Purity>98%| CAS: 1235560-28-7|Molecule Formular: C20H20ClF2N3O3S|MW: 455.91|Other Namess: ABT639,ABT 639
ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).
in vitro: ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50 > 30 μM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents.
in vivo: Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED50 = 2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain. The antinociceptive profile of ABT-639 provides novel insights into the role of peripheral T-type (Cav3.2) channels in chronic pain states.
For research only, not for human use.
GSK163090|GSK-163090|5-HT1A/B/D receptor antagonist
GSK163090|GSK-163090|5-HT1A/B/D receptor antagonist
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.
Product name: GSK163090|Purity>98%| CAS: 844903-58-8|Molecule Formular: C25H29N5O|MW: 415.53|Other Namess: GSK-163090,GSK 163090
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.
in vitro: GSK163090 demonstrates clear dose-dependent inhibition of the 8-OH-DPAT-induced hyperlocomotor activity (hLMA), with ED50 values ranging from 0.03 to 1 mg/kg. GSK163090 was devoid of agonist activity at R1 receptors, but rather it demonstrated amoderate functional antagonismof the phenylephrineinduced contraction of rabbit aorta (pIC50=6.9). [1]
in vivo: Fromamong these analogues, the cyclic urea derivative, GSK163090, emerged due to its low hERG affinity and excellent in vitro DMPK profile. The superior quality of GSK163090 was further highlighted by its commendable in vivo pharmacokinetic
profile in rat and its outstanding activity in the 5-HT1A PD model, where 50% efficacy was achieved at a blood concentration of 3 ng/mL. On the basis of these results and its promising preclinical developability profile, GSK163090 was selected as an appropriate development candidate for progression toward clinical proof-of-concept studies.
For research only, not for human use.
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.
Product name: GSK163090|Purity>98%| CAS: 844903-58-8|Molecule Formular: C25H29N5O|MW: 415.53|Other Namess: GSK-163090,GSK 163090
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively.
in vitro: GSK163090 demonstrates clear dose-dependent inhibition of the 8-OH-DPAT-induced hyperlocomotor activity (hLMA), with ED50 values ranging from 0.03 to 1 mg/kg. GSK163090 was devoid of agonist activity at R1 receptors, but rather it demonstrated amoderate functional antagonismof the phenylephrineinduced contraction of rabbit aorta (pIC50=6.9). [1]
in vivo: Fromamong these analogues, the cyclic urea derivative, GSK163090, emerged due to its low hERG affinity and excellent in vitro DMPK profile. The superior quality of GSK163090 was further highlighted by its commendable in vivo pharmacokinetic
profile in rat and its outstanding activity in the 5-HT1A PD model, where 50% efficacy was achieved at a blood concentration of 3 ng/mL. On the basis of these results and its promising preclinical developability profile, GSK163090 was selected as an appropriate development candidate for progression toward clinical proof-of-concept studies.
For research only, not for human use.
BTZ043|BTZ 043|DprE1 inhibitor|DC Chemicals
BTZ043|BTZ 043|DprE1 inhibitor|DC Chemicals
BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
Product name: BTZ043|Purity>98%| CAS: 1161233-85-7|Molecule Formular: C17H16F3N3O5S|MW: 431.39|Other Namess: BTZ043,BTZ-043,BTZ 043
BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
in vitro: The inhibition of BTZ-resistant DprE1 followed the trend observed in the MIC measurements, with the C387G mutant being more resistant to inhibition by PyrBTZ01, PyrBTZ02, and BTZ043 (7- to 9-fold increases in IC50) than the C387S mutant (2.5- to 4-fold increases in IC50).
in vivo: BTZ-043 were administered at 100 mg/kg twice daily by gavage, and sulfamethoxazole/trimethoprim (SXT), at 100 mg/kg sulfamethoxazole, was used as a positive control.
For research only, not for human use.
BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
Product name: BTZ043|Purity>98%| CAS: 1161233-85-7|Molecule Formular: C17H16F3N3O5S|MW: 431.39|Other Namess: BTZ043,BTZ-043,BTZ 043
BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
in vitro: The inhibition of BTZ-resistant DprE1 followed the trend observed in the MIC measurements, with the C387G mutant being more resistant to inhibition by PyrBTZ01, PyrBTZ02, and BTZ043 (7- to 9-fold increases in IC50) than the C387S mutant (2.5- to 4-fold increases in IC50).
in vivo: BTZ-043 were administered at 100 mg/kg twice daily by gavage, and sulfamethoxazole/trimethoprim (SXT), at 100 mg/kg sulfamethoxazole, was used as a positive control.
For research only, not for human use.
CHIR99021 HCl|DC Chemicals
CHIR99021 HCl|DC Chemicals
CHIR-99021 HCl is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.
Product name: CHIR-99021 HCl|Purity>98%| CAS: 252917-06-9 (free base)|Molecule Formular: C22H18Cl2N8.HCl|MW: 501.8|Other Namess: CHIR99021, CHIR 99021
For research only, not for human use.
CHIR-99021 HCl is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.
Product name: CHIR-99021 HCl|Purity>98%| CAS: 252917-06-9 (free base)|Molecule Formular: C22H18Cl2N8.HCl|MW: 501.8|Other Namess: CHIR99021, CHIR 99021
For research only, not for human use.
MRT68921|MRT 68921|cas 1190379-70-4|DC Chemicals
MRT68921|MRT 68921|cas 1190379-70-4|DC Chemicals
MRT68921 is a potent and dual autophagy kinase ULK1/2 inhibitor with IC50 of 2.9 nM and 1.1 nM, respectively.
Product name: MRT68921 hydrochloride|Purity>98%| CAS: 1190379-70-4|Molecule Formular: C25H34N6O·xHCl|MW: 434.58 (free base)|Other Namess: MRT68921,MRT-68921,MRT 68921
For research only, not for human use.
MRT68921 is a potent and dual autophagy kinase ULK1/2 inhibitor with IC50 of 2.9 nM and 1.1 nM, respectively.
Product name: MRT68921 hydrochloride|Purity>98%| CAS: 1190379-70-4|Molecule Formular: C25H34N6O·xHCl|MW: 434.58 (free base)|Other Namess: MRT68921,MRT-68921,MRT 68921
For research only, not for human use.
Tipifarnib|cas 192185-72-1|DC Chemicals
Tipifarnib|cas 192185-72-1|DC Chemicals
Tipifarnib (IND 58359; R115777) is a potent and specific farnesyltransferase inhibitor with an IC50 of 0.6 nM.
Product name: Tipifarnib|Purity>98%| CAS: 192185-72-1|Molecule Formular: C27H22Cl2N4O|MW: 489.4|Other Namess: Zarnestra; IND 58359; R115777; IND-58359; IND58359; R-115777; R 115777
Tipifarnib (IND 58359; R115777) is a potent and specific farnesyltransferase inhibitor with an IC50 of 0.6 nM.
Tipifarnib is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib (Zarnestra; IND 58359; R115777) binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, it prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.
For research only, not for human use.
Tipifarnib (IND 58359; R115777) is a potent and specific farnesyltransferase inhibitor with an IC50 of 0.6 nM.
Product name: Tipifarnib|Purity>98%| CAS: 192185-72-1|Molecule Formular: C27H22Cl2N4O|MW: 489.4|Other Namess: Zarnestra; IND 58359; R115777; IND-58359; IND58359; R-115777; R 115777
Tipifarnib (IND 58359; R115777) is a potent and specific farnesyltransferase inhibitor with an IC50 of 0.6 nM.
Tipifarnib is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib (Zarnestra; IND 58359; R115777) binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, it prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.
For research only, not for human use.
BMS-707035 (CAS 729607-74-3)|HIV-I integrase inhibitor
BMS-707035 (CAS 729607-74-3)|HIV-I integrase inhibitor
BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity.
Product name: BMS-707035|Purity>98%| CAS: 729607-74-3|Molecule Formular: C17H19FN4O5S|MW: 410.42|Other Namess: BMS 707035，BMS707035
BMS-707035 is a pyrimidine carboxamide similar to Raltegravir. BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity. BMS-707035 binding and target DNA binding to IN are mutually exclusive events, as elucidated by the fact that increasing the amount of target DNA overcomes the inhibition of strand transfer catalysis by BMS-707035. BMS-707035 binding affinity to IN is also affected by the four terminal bases at the 5’ end of the pre-processed U5 long terminal repeat (LTR).
For research only, not for human use.
BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity.
Product name: BMS-707035|Purity>98%| CAS: 729607-74-3|Molecule Formular: C17H19FN4O5S|MW: 410.42|Other Namess: BMS 707035，BMS707035
BMS-707035 is a pyrimidine carboxamide similar to Raltegravir. BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity. BMS-707035 binding and target DNA binding to IN are mutually exclusive events, as elucidated by the fact that increasing the amount of target DNA overcomes the inhibition of strand transfer catalysis by BMS-707035. BMS-707035 binding affinity to IN is also affected by the four terminal bases at the 5’ end of the pre-processed U5 long terminal repeat (LTR).
For research only, not for human use.
CVM-1118|vasculogenic mimicry (VM) inhibitor
CVM-1118|vasculogenic mimicry (VM) inhibitor
CVM-1118(CVM1118) has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM).
Product name: CVM-1118(CVM1118)|Purity>98%| CAS: N/A|Molecule Formular: C16H11FNNa2O5P|MW: 393.21|Other Namess: CVM-1118,CVM 1118
CVM-1118 is a small molecule NCE (new chemical entity). It has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). CVM-1118 is currently being developed into a next generation oral anti-cancer drug. CVM-1118 has great potential showing inhibitory effect towards breast, ovarian, colon, and liver cancer in animal models.
For research only, not for human use.
CVM-1118(CVM1118) has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM).
Product name: CVM-1118(CVM1118)|Purity>98%| CAS: N/A|Molecule Formular: C16H11FNNa2O5P|MW: 393.21|Other Namess: CVM-1118,CVM 1118
CVM-1118 is a small molecule NCE (new chemical entity). It has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). CVM-1118 is currently being developed into a next generation oral anti-cancer drug. CVM-1118 has great potential showing inhibitory effect towards breast, ovarian, colon, and liver cancer in animal models.
For research only, not for human use.
Staurosporine|cas 62996-74-1
Staurosporine|cas 62996-74-1
Staurosporine is a prototypical potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.
Product name: Staurosporine|Purity>98%| CAS: 62996-74-1|Molecule Formular: C28H26N4O3|MW: 466.53|Other Namess:
For research only, not for human use.
Staurosporine is a prototypical potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.
Product name: Staurosporine|Purity>98%| CAS: 62996-74-1|Molecule Formular: C28H26N4O3|MW: 466.53|Other Namess:
For research only, not for human use.
SMER28 |SMER-28|cas 307538-42-7
SMER28 |SMER-28|cas 307538-42-7
HUHS015 is a prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) inhibitor.
Product name: HUHS015|Purity>98%| CAS: 1453097-13-6|Molecule Formular: C11H10BrN3|MW: 264.1|Other Namess: HUHS-015,HUHS 015
For research only, not for human use.
HUHS015 is a prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) inhibitor.
Product name: HUHS015|Purity>98%| CAS: 1453097-13-6|Molecule Formular: C11H10BrN3|MW: 264.1|Other Namess: HUHS-015,HUHS 015
For research only, not for human use.
SMER28 |SMER-28|cas 307538-42-7
SMER28 |SMER-28|cas 307538-42-7
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells when supplied at 47 µM.
Product name: SMER28|Purity>98%| CAS: 307538-42-7|Molecule Formular: C11H10BrN3|MW: 264.1|Other Namess: SMER-28,SMER 28
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells when supplied at 47 µM.It increases autophagosome synthesis and enhances clearance of aggregate-prone substrates, including those relevant to Huntington’s, Parkinson’s, and Alzheimer’s diseases.SMER28 promotes reprogramming of fibroblasts into neural stem cells when used in combination with other chemical reagents.
For research only, not for human use.
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells when supplied at 47 µM.
Product name: SMER28|Purity>98%| CAS: 307538-42-7|Molecule Formular: C11H10BrN3|MW: 264.1|Other Namess: SMER-28,SMER 28
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells when supplied at 47 µM.It increases autophagosome synthesis and enhances clearance of aggregate-prone substrates, including those relevant to Huntington’s, Parkinson’s, and Alzheimer’s diseases.SMER28 promotes reprogramming of fibroblasts into neural stem cells when used in combination with other chemical reagents.
For research only, not for human use.
BH3I-1 |Bcl-xL inhibitor|CAS 300817-68-9
BH3I-1 |Bcl-xL inhibitor|CAS 300817-68-9
BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL. BH3I-1 is an inhibitor of Bcl-xL.
Product name: BH3I-1 |Purity>98%| CAS: 300817-68-9|Molecule Formular: C15H14BrNO3S2|MW: 400.3|Other Namess: BH3I 1 ，BH3I1
For research only, not for human use.
BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL. BH3I-1 is an inhibitor of Bcl-xL.
Product name: BH3I-1 |Purity>98%| CAS: 300817-68-9|Molecule Formular: C15H14BrNO3S2|MW: 400.3|Other Namess: BH3I 1 ，BH3I1
For research only, not for human use.
IQ-1S |JNK3 inhibitor|CAS 23146-22-7
IQ-1S |JNK3 inhibitor|CAS 23146-22-7
IQ-1S is a selective JNK3 inhibitor (IC50 values are 390, 360 and 87 nM for JNK1, 2 and 3 respectively).
Product name: IQ-1S |Purity>98%| CAS: 23146-22-7|Molecule Formular: C15H9N3O|MW: 247.25|Other Namess: IQ-1S ,IQ 1S ,IQ1S
Selective JNK3 inhibitor (IC50 values are 390, 360 and 87 nM for JNK1, 2 and 3 respectively). Inhibits JNK phosphorylation and NFκB /AP-1 transcriptional activity. Shows immunosuppressant effects in vivo.
For research only, not for human use.
IQ-1S is a selective JNK3 inhibitor (IC50 values are 390, 360 and 87 nM for JNK1, 2 and 3 respectively).
Product name: IQ-1S |Purity>98%| CAS: 23146-22-7|Molecule Formular: C15H9N3O|MW: 247.25|Other Namess: IQ-1S ,IQ 1S ,IQ1S
Selective JNK3 inhibitor (IC50 values are 390, 360 and 87 nM for JNK1, 2 and 3 respectively). Inhibits JNK phosphorylation and NFκB /AP-1 transcriptional activity. Shows immunosuppressant effects in vivo.
For research only, not for human use.
Madrasin|pre-mRNA splicing tool compound
Madrasin|pre-mRNA splicing tool compound
Madrasin inhibits pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA.
Product name: Madrasin|Purity>98%| CAS: 374913-63-0 |Molecule Formular: C16H17N5O2|MW: 311.34|Other Namess:
For research only, not for human use.
Madrasin inhibits pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA.
Product name: Madrasin|Purity>98%| CAS: 374913-63-0 |Molecule Formular: C16H17N5O2|MW: 311.34|Other Namess:
For research only, not for human use.
Savolitinib|Volitinib|HMPL-504; AZD-6094
Savolitinib|Volitinib|HMPL-504; AZD-6094
Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
Product name: Volitinib(Savolitinib)|Purity>98%| CAS: 1313725-88-0|Molecule Formular: C17H15N9|MW: 345.36|Other Namess: Volitinib; HMPL504; AZD-6094,Volitinib; HMPL-504; AZD6094; HMPL 504; AZD 6094
Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.
For research only, not for human use.
Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
Product name: Volitinib(Savolitinib)|Purity>98%| CAS: 1313725-88-0|Molecule Formular: C17H15N9|MW: 345.36|Other Namess: Volitinib; HMPL504; AZD-6094,Volitinib; HMPL-504; AZD6094; HMPL 504; AZD 6094
Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.
For research only, not for human use.
Piperlongumine|CAS 20069-09-4|DC Chemicals
Piperlongumine|CAS 20069-09-4|DC Chemicals
Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53.
Product name: Piperlongumine|Purity>98%| CAS: 20069-09-4|Molecule Formular: C17H19NO5|MW: 317.34|Other Namess:
Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53. Also inhibits the growth of spontaneous malignant breast tumors in mice. Displays little effect on normal cells. Rapidly depletes androgen receptor expression in human prostate cancer cells via a ROS-dependent, proteasome-mediated mechanism.
For research only, not for human use.
Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53.
Product name: Piperlongumine|Purity>98%| CAS: 20069-09-4|Molecule Formular: C17H19NO5|MW: 317.34|Other Namess:
Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53. Also inhibits the growth of spontaneous malignant breast tumors in mice. Displays little effect on normal cells. Rapidly depletes androgen receptor expression in human prostate cancer cells via a ROS-dependent, proteasome-mediated mechanism.
For research only, not for human use.
Sinogliatin (RO5305552)|glucokinase (GCK/GK) activator
Sinogliatin (RO5305552)|glucokinase (GCK/GK) activator
Sinogliatin (HMS5552, RO5305552) is a mall molecule glucokinase (GCK; GK) activator
Product name: Sinogliatin (HMS5552, RO5305552)|Purity>98%| CAS: N/A|Molecule Formular: C22H27ClN4O5|MW: 462.93|Other Namess: HM-S5552, RO-5305552,HM S5552, RO 5305552
For research only, not for human use.
Sinogliatin (HMS5552, RO5305552) is a mall molecule glucokinase (GCK; GK) activator
Product name: Sinogliatin (HMS5552, RO5305552)|Purity>98%| CAS: N/A|Molecule Formular: C22H27ClN4O5|MW: 462.93|Other Namess: HM-S5552, RO-5305552,HM S5552, RO 5305552
For research only, not for human use.
Danirixin(GSK1325756)|CXCR2 antagonist
Danirixin(GSK1325756)|CXCR2 antagonist
Danirixin(GSK1325756) is a selective CXCR2 antagonist.
Product name: Danirixin(GSK1325756)|Purity>98%| CAS: 954126-98-8|Molecule Formular: C19H21ClFN3O4S|MW: 441.9|Other Namess: Danirixin,GSK 1325756,GSK-1325756
Danirixin is a selective and reversible C-X-C Chemokine Receptor 2 (CXCR2) antagonist that inhibits neutrophil transmigration and activation to areas of inflammation.
For research only, not for human use.
Danirixin(GSK1325756) is a selective CXCR2 antagonist.
Product name: Danirixin(GSK1325756)|Purity>98%| CAS: 954126-98-8|Molecule Formular: C19H21ClFN3O4S|MW: 441.9|Other Namess: Danirixin,GSK 1325756,GSK-1325756
Danirixin is a selective and reversible C-X-C Chemokine Receptor 2 (CXCR2) antagonist that inhibits neutrophil transmigration and activation to areas of inflammation.
For research only, not for human use.
WST-8 for CCK-8 |CAS 193149-74-5|tetrazolium reagent
WST-8 for CCK-8 |CAS 193149-74-5|tetrazolium reagent
WST-8 is a next generation tetrazolium reagent that serves as a sensitive chromogenic indicator for NADH.
Product name: WST-8|Purity>98%| CAS: 193149-74-5|Molecule Formular: C20H13N6NaO11S2|MW: 600.47|Other Namess: WST8,WST 8
WST-8 is a next generation tetrazolium reagent that serves as a sensitive chromogenic indicator for NADH. It is reduced by NADH at neutral pHs in the presence of 1-methoxy PMS to produce the corresponding formazan dye that absorbs at 460 nM. Useful as a cell viability indicator in cell proliferation assays.
For research only, not for human use.
WST-8 is a next generation tetrazolium reagent that serves as a sensitive chromogenic indicator for NADH.
Product name: WST-8|Purity>98%| CAS: 193149-74-5|Molecule Formular: C20H13N6NaO11S2|MW: 600.47|Other Namess: WST8,WST 8
WST-8 is a next generation tetrazolium reagent that serves as a sensitive chromogenic indicator for NADH. It is reduced by NADH at neutral pHs in the presence of 1-methoxy PMS to produce the corresponding formazan dye that absorbs at 460 nM. Useful as a cell viability indicator in cell proliferation assays.
For research only, not for human use.
Ro 41-1049 hydrochloride |(CAS 127500-84-9)
Ro 41-1049 hydrochloride |(CAS 127500-84-9)
Ro 41-1049 hydrochloride is a selective, reversible inhibitor of MAO-A.
Product name: Ro 41-1049 hydrochloride|Purity>98%| CAS: 127500-84-9|Molecule Formular: C12H12FN3OS.HCl|MW: 301.77|Other Namess: Ro41 1049, Ro 41 1049
For research only, not for human use.
Ro 41-1049 hydrochloride is a selective, reversible inhibitor of MAO-A.
Product name: Ro 41-1049 hydrochloride|Purity>98%| CAS: 127500-84-9|Molecule Formular: C12H12FN3OS.HCl|MW: 301.77|Other Namess: Ro41 1049, Ro 41 1049
For research only, not for human use.
Evatanepag (CP-533536)|cas 223488-57-1
Evatanepag (CP-533536)|cas 223488-57-1
Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.
Product name: Evatanepag (CP-533536)|Purity>98%| CAS: 223488-57-1|Molecule Formular: C25H28N2O5S|MW: 468.57|Other Namess: CP-533536,CP 533536,CP533536
CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.
For research only, not for human use.
Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.
Product name: Evatanepag (CP-533536)|Purity>98%| CAS: 223488-57-1|Molecule Formular: C25H28N2O5S|MW: 468.57|Other Namess: CP-533536,CP 533536,CP533536
CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets.
For research only, not for human use.
EL102|EL-102|CAS 1233948-61-2
EL102|EL-102|CAS 1233948-61-2
EL-102 is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade.
Product name: EL102|Purity>98%| CAS: 1233948-61-2|Molecule Formular: C19H16N2O3S2|MW: 384.47|Other Namess: EL-102, EL 102
EL102 is a novel toluidine sulphonamide, was developed from a phenotypic screen to develop novel small molecule inhibitors of the hypoxia signalling cascade. It is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade. The drug has equal activity against normoxic and hypoxic tumour cells indicating that it may be equally active in these different tumour compartments.
For research only, not for human use.
EL-102 is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade.
Product name: EL102|Purity>98%| CAS: 1233948-61-2|Molecule Formular: C19H16N2O3S2|MW: 384.47|Other Namess: EL-102, EL 102
EL102 is a novel toluidine sulphonamide, was developed from a phenotypic screen to develop novel small molecule inhibitors of the hypoxia signalling cascade. It is a dual-inhibitor of apoptosis and angiogenesis, and exerts its action though the inhibition of Hif1 alpha induced hypoxic signalling pathways and induction of the Caspase 3/7 apoptotic cascade. The drug has equal activity against normoxic and hypoxic tumour cells indicating that it may be equally active in these different tumour compartments.
For research only, not for human use.
ONO4059-Analog(BTK inhibitor)| cas 1351636-18-4
ONO4059-Analog(BTK inhibitor)| cas 1351636-18-4
ONO4059-Analog, is a potent and selective BTK inhibitor, and is a structural analogue of ONO-4059.
Product name: ONO4059-Analog(BTK inhibitor)|Purity>98%| CAS: 1351636-18-4|Molecule Formular: C25H24N6O3|MW: 456.51|Other Namess: ON 0459 ANALOG,ON-0459 ANALOG,ONO BTK
ONO4059-Analog, CAS#1351635-67-0, is a potent and selective BTK inhibitor, and is a structural analogue of ONO-4059. ONO4059 is currently under clinical trials.
For research only, not for human use.
ONO4059-Analog, is a potent and selective BTK inhibitor, and is a structural analogue of ONO-4059.
Product name: ONO4059-Analog(BTK inhibitor)|Purity>98%| CAS: 1351636-18-4|Molecule Formular: C25H24N6O3|MW: 456.51|Other Namess: ON 0459 ANALOG,ON-0459 ANALOG,ONO BTK
ONO4059-Analog, CAS#1351635-67-0, is a potent and selective BTK inhibitor, and is a structural analogue of ONO-4059. ONO4059 is currently under clinical trials.
For research only, not for human use.
ML-264,ML264|KLF5 inhibitor
ML-264,ML264|KLF5 inhibitor
ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5).
Product name: ML-264|Purity>98%| CAS: 1550008-55-3|Molecule Formular: C17H21ClN2O4S|MW: 384.87|Other Namess: ML-264; ML264; ML 264; CID-51003603
ML-264 is a Krüppel-like factor 5 (KLF5) inhibitor That Potently Inhibits Growth of Colorectal Cancer. ML264 is highly active (IC50 = 29 nM is a cell-based assay for proliferation of DLD-1 cells, IC50 = 81 nM in a cell-based luciferase assay). It lacks cytotoxicity in the IEC-6 control cell line (IC50 >50 μM, <50% inhibition was observed at 100 μM). Robust activity was also seen in several other KLF5-expressing cell types as well (e.g., HCT116, IC50 = 560 nM; HT29, IC50 = 130 nM; SW620, IC50 = 430 nM). ML264 is a good candidate for in vivo anticancer studies, with great potential for use in long time-course in situ studies aimed to elucidate the role of KLF5 as a regulator of cellular proliferation and tumor formation in the intestinal epithelium.
For research only, not for human use.
ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5).
Product name: ML-264|Purity>98%| CAS: 1550008-55-3|Molecule Formular: C17H21ClN2O4S|MW: 384.87|Other Namess: ML-264; ML264; ML 264; CID-51003603
ML-264 is a Krüppel-like factor 5 (KLF5) inhibitor That Potently Inhibits Growth of Colorectal Cancer. ML264 is highly active (IC50 = 29 nM is a cell-based assay for proliferation of DLD-1 cells, IC50 = 81 nM in a cell-based luciferase assay). It lacks cytotoxicity in the IEC-6 control cell line (IC50 >50 μM, <50% inhibition was observed at 100 μM). Robust activity was also seen in several other KLF5-expressing cell types as well (e.g., HCT116, IC50 = 560 nM; HT29, IC50 = 130 nM; SW620, IC50 = 430 nM). ML264 is a good candidate for in vivo anticancer studies, with great potential for use in long time-course in situ studies aimed to elucidate the role of KLF5 as a regulator of cellular proliferation and tumor formation in the intestinal epithelium.
For research only, not for human use.
Pamapimod（R-1503,Ro4402257),p38 inhibitor
Pamapimod（R-1503,Ro4402257),p38 inhibitor
Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.
Product name: Pamapimod（R-1503）|Purity>98%| CAS: 449811-01-2|Molecule Formular: C19H20F2N4O4 |MW: 406.38 |Other Namess: Pamapimod; R 1503; R1503; R-1503; Ro 4402257; Ro4402257; Ro-4402257
Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.Pamapimod inhibited p38alpha and p38beta enzymatic activity, with IC(50) values of 0.014 +/- 0.002 and 0.48 +/- 0.04 microM, respectively. There was no activity against p38delta or p38gamma isoforms. When profiled across 350 kinases, pamapimod bound only to four kinases in addition to p38. Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH(2)-terminal kinase (JNK), respectively. Pamapimod inhibited p38 (IC(50), 0.06 microM), but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) alpha production by monocytes, interleukin (IL)-1beta production in human whole blood, and spontaneous TNFalpha production by synovial explants from RA patients. Pamapimod is a potent, selective inhibitor of p38alpha with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.
For research only, not for human use.
Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.
Product name: Pamapimod（R-1503）|Purity>98%| CAS: 449811-01-2|Molecule Formular: C19H20F2N4O4 |MW: 406.38 |Other Namess: Pamapimod; R 1503; R1503; R-1503; Ro 4402257; Ro4402257; Ro-4402257
Pamapimod（R-1503）is a novel p38 MAP kinase inhibitor.Pamapimod inhibited p38alpha and p38beta enzymatic activity, with IC(50) values of 0.014 +/- 0.002 and 0.48 +/- 0.04 microM, respectively. There was no activity against p38delta or p38gamma isoforms. When profiled across 350 kinases, pamapimod bound only to four kinases in addition to p38. Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH(2)-terminal kinase (JNK), respectively. Pamapimod inhibited p38 (IC(50), 0.06 microM), but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) alpha production by monocytes, interleukin (IL)-1beta production in human whole blood, and spontaneous TNFalpha production by synovial explants from RA patients. Pamapimod is a potent, selective inhibitor of p38alpha with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.
For research only, not for human use.
NVP-BAW2881,NVP-BAW 2881|VEGFR inhibitor
NVP-BAW2881,NVP-BAW 2881|VEGFR inhibitor
NVP-BAW2881 is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor
Product name: NVP-BAW2881|Purity>98%| CAS: 861875-60-7 |Molecule Formular: C22H15F3N4O2 |MW: 424.11|Other Namess: NVP-BAW2881,NVP-BAW-2881,,NVP-BAW 2881
BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro. NVP-BAW2881 reduced the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.
For research only, not for human use.
NVP-BAW2881 is a novel vascular endothelial growth factor (VEGF) receptor tyrosine-kinase inhibitor
Product name: NVP-BAW2881|Purity>98%| CAS: 861875-60-7 |Molecule Formular: C22H15F3N4O2 |MW: 424.11|Other Namess: NVP-BAW2881,NVP-BAW-2881,,NVP-BAW 2881
BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro. NVP-BAW2881 reduced the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.
For research only, not for human use.
订阅：
博文 (Atom)